Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm Metastasis × osimertinib × Clear all

Phase

Status

Completed 4 Active not recruiting 4 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 32 Lung Neoplasms 11 Neoplasms 2 NSCLC 2 Carcinoma 2 Breast Neoplasms 2 Brain Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sexual Dysfunction, Physiological 1 Non-Small Cell Lung Cancer With EGFR Mutation 1 Non Small Cell Lung Cancer Metastatic 1 Neoplasm Metastasis 1 NSCLC Patients With Brain Metastasis 1 Mesothelioma 1 Meningeal Carcinomatosis 1 Lung Cancer Metastatic 1 Locally Advanced or Metastatic Non-squamous NSCLC 1 Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1 Head and Neck Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 43 Specimen Handling 28 Magnetic Resonance Spectroscopy 24 Biopsy 24 Radiosurgery 17 Gemcitabine 14 Nivolumab 12 Cisplatin 11 Paclitaxel 10 Cyclophosphamide 10 Carboplatin 10 Capecitabine 9 Taxes 8 Pemetrexed 8 Leucovorin 8 Irinotecan 8 Fluorouracil 8 Cetuximab 8 Bevacizumab 8 trastuzumab deruxtecan 7 Oxaliplatin 7 Drug Therapy 7 Doxorubicin 7 olaparib 6 cemiplimab 6 abemaciclib 6 Radiotherapy 6 Folfox protocol 6 Docetaxel 6 ribociclib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05261399 2025-01-10

SAFFRON

AstraZeneca

Phase 3 Recruiting

Carcinoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡